Smith & Nephew’s (SN) “Buy” Rating Reaffirmed at Jefferies Financial Group

Smith & Nephew (LON:SN)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Financial Group in a research report issued to clients and investors on Wednesday,London Stock Exchange reports. They currently have a GBX 1,500 target price on the stock. Jefferies Financial Group’s price target suggests a potential upside of 33.69% from the company’s current price.

Other research analysts have also issued reports about the stock. Berenberg Bank restated a “hold” rating and issued a GBX 13 target price on shares of Smith & Nephew in a report on Friday, May 1st. Citigroup downgraded shares of Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Shore Capital Group reissued a “buy” rating and issued a GBX 1,000 price objective on shares of Smith & Nephew in a research report on Tuesday, July 21st. Royal Bank Of Canada reissued a “sector perform” rating and set a GBX 1,350 price objective on shares of Smith & Nephew in a research note on Monday, June 29th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,400 target price on shares of Smith & Nephew in a research report on Thursday, July 30th. Four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of GBX 1,200.11.

Smith & Nephew Stock Performance

Smith & Nephew stock traded down GBX 75 during midday trading on Wednesday, reaching GBX 1,122. 5,541,759 shares of the company were exchanged, compared to its average volume of 343,671. The firm has a market capitalization of £12.30 billion, a P/E ratio of 40.40, a price-to-earnings-growth ratio of 0.46 and a beta of 0.69. The company’s 50-day moving average is GBX 1,136.07 and its 200-day moving average is GBX 1,194.74. The company has a quick ratio of 0.84, a current ratio of 2.57 and a debt-to-equity ratio of 62.90.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.